Of these, only seven produced 50% solubility (SMPX_HUMAN, HBP1_HUMAN, IPKA_HUMAN), the others were either present in very low amounts (MAR1_HUMAN, APR_HUMAN) or were not solubilized at all (STP1_HUMAN, BTG1_HUMAN, MGN_HUMAN) [64, 65]
Disclosures: Kali Zhou: Gilead Sciences Inc: Grant/Research Support, Christopher Wong: Nothing to Disclose, Aaron Ahearn: Nothing to Disclose, Jeffrey Kahn: Orphalon: Single Advisory Board meeting 11/2023, Malinckrodt: Attended speaker's training session, never spoke, Orphalon: Single advisory board meeting, 2023, Norah Terrault: Elseiver: Royalties or patent beneficiary, GSK: Grant/Research Support, Eiger Pharmaceuticals: Grant/Research Support, Helio Health: Grant/Research Support, Durect Corp: Grant/Research Support, ImmunoCore: Grant/Research Support, HBV Foundation: Board member, AASLD: Executive role 1207 ASSESSING THE PREVALENCE OF CARDIOMETABOLIC RISK FACTORS IN PATIENTS REFERRED TO A STEATOTIC LIVER DISEASE CLINIC Yousef Almahanna 1 Ahmed Almohsen 1 Yi Nong Song 1 Amani Bajunayd 1 Jeemin Kim 1 Adrienne Abaya 1 Rokhsana Mortuza 1 Mohammad Qasim Khan 1 Juan Pablo Arab 1 , 1 University of Western Ontario Background: The metabolic syndrome is a known risk factor for development of hepatic steatosis
Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, Kronstedt S, Lipshultz LI, Khera M
Stockwell BR, Jiang X (2020) The chemistry and biology of ferroptosis
